Design Therapeutics, Inc. (DSGN) has a negative trailing P/E of -10.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -9.79%.
Criteria proven by this page:
Overall SharesGrow Score: 41/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -551.1 | 0.00 | -309.75 | 1,352,653.60 | - |
| 2020 | -136.2 | -0.46 | -99.70 | 0.00 | - |
| 2021 | -27.7 | -0.18 | 2.57 | 0.00 | - |
| 2022 | -9.0 | -0.19 | 1.75 | 0.00 | - |
| 2023 | -2.2 | -0.51 | 0.53 | 0.00 | - |
| 2024 | -7.0 | 0.27 | 1.44 | 0.00 | - |
| 2025 | -7.7 | -0.20 | 2.53 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.08 | $834.00 | $-2.05M | -245443.6% |
| 2020 | $-0.30 | $226.00 | $-8.28M | -3663716.8% |
| 2021 | $-0.77 | $0.00 | $-35.53M | - |
| 2022 | $-1.05 | $0.00 | $-58.62M | - |
| 2023 | $-1.19 | $0.00 | $-66.86M | - |
| 2024 | $-0.88 | $0.00 | $-49.59M | - |
| 2025 | $-1.22 | $0.00 | $-69.79M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.36 | $-1.56 – $-1.20 | $117.33M | $117.33M – $117.33M | 4 |
| 2027 | $-1.64 | $-1.91 – $-1.42 | $204.78M | $204.78M – $204.78M | 4 |
| 2028 | $-2.01 | $-2.38 – $-1.61 | $8.5M | $8.5M – $8.5M | 4 |
| 2029 | $-1.61 | $-1.61 – $-1.61 | $69.26M | $69.26M – $69.26M | 2 |
| 2030 | $-0.41 | $-0.41 – $-0.41 | $224.42M | $224.42M – $224.42M | 2 |
